-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $600

Benzinga·11/03/2026 15:13:50
Listen to the news
RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $576 to $600.